about the author

David Gilham

VP of R&D, Celyad

Dr. David Gilham first joined Celyad in April 2016 as member of the Scientific Advisory Board. He is now Vice-President R&D, heading the implementation of Celyad's R&D strategy for programs in immuno-oncology. Dr. Gilham received his Ph.D in Molecular Pharmacology at the University of Dundee prior to moving to Bristol University in 1996 to work on CAR T cells with Professor Robert Hawkins. Prior to joining Celyad, David was a Reader in the Institute of Cancer Sciences, University of Manchester, UK and led the Clinical and Experimental Immunotherapy Group based within the Manchester Cancer Research Centre.